ATE437640T1 - Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern - Google Patents

Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern

Info

Publication number: ATE437640T1
Authority: AT; Austria
Prior art keywords: modulators; binding cassette; oxazoles; thiazoles; atp binding
Prior art date: 2003-11-14

Application number

AT04811321T

Other languages

English (en)

Inventor

Ruah Sarah Hadida

Mark Miller

Peter Grootenhuis

Matthew Hamilton

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-14

Filing date

2004-11-15

Publication date

2009-08-15

2004-11-15 Application filed by Vertex Pharma filed Critical Vertex Pharma

2009-08-15 Application granted granted Critical

2009-08-15 Publication of ATE437640T1 publication Critical patent/ATE437640T1/de

Links

108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title abstract 2
102000005416 ATP-Binding Cassette Transporters Human genes 0.000 title abstract 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title 1
108010078791 Carrier Proteins Proteins 0.000 abstract 1
201000003883 Cystic fibrosis Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)

AT04811321T 2003-11-14 2004-11-15 Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern ATE437640T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52035503P	2003-11-14	2003-11-14
PCT/US2004/038566 WO2005049018A1 (en)	2003-11-14	2004-11-15	Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters

Publications (1)

Publication Number	Publication Date
ATE437640T1 true ATE437640T1 (de)	2009-08-15

Family

ID=34619457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04811321T ATE437640T1 (de)	2003-11-14	2004-11-15	Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern

Country Status (16)

Country	Link
US (3)	US7407976B2 (de)
EP (2)	EP2140865A1 (de)
JP (1)	JP4869072B2 (de)
KR (1)	KR20060121185A (de)
CN (2)	CN101675928A (de)
AT (1)	ATE437640T1 (de)
AU (1)	AU2004290581B2 (de)
CA (1)	CA2545719A1 (de)
DE (1)	DE602004022319D1 (de)
ES (1)	ES2328824T3 (de)
MX (1)	MXPA06005343A (de)
NO (1)	NO20062773L (de)
NZ (1)	NZ547220A (de)
RU (1)	RU2006120549A (de)
WO (1)	WO2005049018A1 (de)
ZA (1)	ZA200604578B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006517234A (ja) *	2003-02-10	2006-07-20	アムジエン・インコーポレーテツド	バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
JP4869072B2 (ja) *	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
ATE512145T1 (de) *	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
EP1945632B1 (de)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterozyklische modulatoren von atp-bindenden kassettentransportern
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
AU2006336504C9 (en) *	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
BRPI0710479A2 (pt) *	2006-01-18	2012-08-14	Hoffmann La Roche	composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.
US7524848B2 (en)	2006-03-23	2009-04-28	Amgen Inc.	Diaza heterocyclic amide compounds and their uses
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
JP5182088B2 (ja)	2006-04-19	2013-04-10	アステラス製薬株式会社	アゾールカルボキサミド誘導体
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US7754739B2 (en) *	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
WO2008073461A2 (en) *	2006-12-11	2008-06-19	Wyeth	Ion channel modulators
GB0701426D0 (en) *	2007-01-25	2007-03-07	Univ Sheffield	Compounds and their use
EP2142498A2 (de) *	2007-04-02	2010-01-13	Institute for Oneworld Health	Cftr-hemmer-verbindungen und verwendungen davon
EP2152276A4 (de) *	2007-05-09	2011-09-14	Traffick Therapeutics Inc	Screening-assay zur identifizierung von korrektoren für proteintransportstörungen
US8969386B2 (en)	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
HRP20151052T1 (xx)	2007-07-19	2015-11-06	H. Lundbeck A/S	Peteroäślani heterocikliäśki amidi i srodne tvari
HUE028426T2 (en)	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
EP2206707B1 (de)	2007-10-24	2014-07-23	Astellas Pharma Inc.	Azolecarboxamidverbindung oder salz daraus
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
WO2009076141A2 (en) *	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2639224B1 (de)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Verfahren zur Herstellung von Cycloalkylcarboxamidopyridinbenzoesäuren
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (de) *	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridylderivate als cftr-modulatoren
US20090264433A1 (en) *	2008-04-21	2009-10-22	Institute For Oneworld Health	Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) *	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
US20090270398A1 (en) *	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131957A2 (en)	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
EP2303275A4 (de) *	2008-06-17	2012-05-09	Univ Duke	Geglättete rezeptormodulatoren
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
JP2012503005A (ja) *	2008-09-19	2012-02-02	インスティテュートフォアワンワールドヘルス	イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
JP2012504143A (ja) *	2008-09-29	2012-02-16	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
NZ592685A (en) *	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
US8511216B2 (en) *	2009-03-30	2013-08-20	Kanzaki Kokyukoki Mfg. Co., Ltd.	Hydraulic actuator unit
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
WO2010123933A1 (en) *	2009-04-20	2010-10-28	Institute For Oneworld Health	Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US20110251253A1 (en)	2010-03-25	2011-10-13	Vertex Pharmaceuticals Incorporated	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2808501A1 (en)	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
IN2014KN00885A (de)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (de)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmazeutische zusammensetzung und verabreichung davon
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
LT3470063T (lt)	2012-11-02	2025-02-10	Vertex Pharmaceuticals Incorporated	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
WO2014210159A1 (en) *	2013-06-26	2014-12-31	Proteostasis Therapeutics, Inc.	Methods of modulating cftr activity
JP6963896B2 (ja)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
CA2942386A1 (en)	2014-03-13	2015-09-17	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en)	2014-03-13	2015-09-17	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing cftr activity
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
CA2952862A1 (en)	2014-06-19	2015-12-23	Proteostasis Therapeutics, Inc.	Compounds, compositions and methods of increasing cftr activity
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
MA41253A (fr)	2014-12-23	2017-10-31	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
CA2971850A1 (en)	2014-12-23	2016-06-30	Proteostasis Therapeutics, Inc.	Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en)	2014-12-23	2020-08-11	Proteostasis Therapeutics, Inc.	Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en)	2014-12-23	2016-06-30	Proteostasis Therapeutics, Inc.	Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA42488A (fr)	2015-07-24	2018-05-30	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
CA3000483C (en)	2015-10-06	2024-02-13	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for modulating cftr
BR112018070747B1 (pt)	2016-04-07	2024-01-09	Proteostasis Therapeutics, Inc	Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
MA45397A (fr)	2016-06-21	2019-04-24	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
SI3519401T1 (sl)	2016-09-30	2022-01-31	Vertex Pharmaceuticals Incorporated	Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh)	2016-12-09	2023-12-08	弗特克斯药品有限公司	囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko)	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en)	2018-02-15	2022-07-07	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (de)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulatoren des transmembranleitfähigkeitsreglers von zystischer fibrose, pharmazeutische zusammensetzungen, behandlungsverfahren und verfahren zur herstellung des modulators
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
CA3150162A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en)	2020-08-13	2023-04-01	Vertex Pharma	Crystal forms of CFTR modulators
EP4225762A1 (de)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulatoren des regulators der transmembran-leitfähigkeit bei zystischer fibrose
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en)	2020-12-10	2023-07-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1318291A (en) *	1970-04-15	1973-05-23	Shell Int Research	Carboxamide derivatives and fungicidal compositions containing them
JPS5041856A (de) *	1973-08-17	1975-04-16
US5244867A (en) *	1989-09-26	1993-09-14	Basf Aktiengesellschaft	Oxazole- and thiazolecarboxamides
DE3932052A1 (de) *	1989-09-26	1991-04-04	Basf Ag	Oxazol- bzw. thiazolcarbonsaeureamide
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
JPH0441425A (ja) *	1990-06-07	1992-02-12	Tanabe Seiyaku Co Ltd	５―リポキシゲナーゼ阻害剤
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
IT1270882B (it) *	1993-10-05	1997-05-13	Isagro Srl	Oligopeptidi ad attivita' fungicida
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
US6096499A (en) *	1996-03-22	2000-08-01	Geron Corporation	Mammalian DNA primase screen and activity modulating agents
FR2751969B1 (fr) *	1996-08-01	1998-12-04	Centre Nat Rech Scient	Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
JPH10338680A (ja) *	1997-06-06	1998-12-22	Takeda Chem Ind Ltd	チアゾール誘導体、その製造法および用途
US6251629B1 (en) *	1997-10-07	2001-06-26	Smithkline Beecham Corporation	ABC transporter
AR019727A1 (es) *	1998-06-30	2002-03-13	Takeda Chemical Industries Ltd	Composicion farmaceutica
JP2002521436A (ja) *	1998-07-28	2002-07-16	スミスクライン・ビーチャム・コーポレイション	置換アニリド化合物および方法
US6399656B1 (en) *	1998-07-28	2002-06-04	Smithkline Beecham Corporation	Compounds and methods
US6096770A (en) *	1998-08-03	2000-08-01	American Home Products Corporation	Anthranilic acid analogs
JP4465779B2 (ja) *	1999-02-10	2010-05-19	大正製薬株式会社	育毛剤
WO2000059905A1 (en) *	1999-04-02	2000-10-12	Neurogen Corporation	ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
AUPQ309399A0 (en) *	1999-09-28	1999-10-21	Fujisawa Pharmaceutical Co., Ltd.	Benzothiazoline derivatives
AUPQ319899A0 (en) *	1999-10-01	1999-10-28	Fujisawa Pharmaceutical Co., Ltd.	Amide compounds
US6479231B1 (en) *	1999-11-23	2002-11-12	Gilead Sciences, Inc.	Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1 (hOAT1)
JP2001278872A (ja) *	2000-03-27	2001-10-10	Banyu Pharmaceut Co Ltd	新規アミノチアゾール誘導体
AR034897A1 (es) *	2001-08-07	2004-03-24	Hoffmann La Roche	Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
EP1432706A2 (de) *	2001-09-26	2004-06-30	Bayer Pharmaceuticals Corporation	3-pyridyl oder 4-isoquinolinylthiazole als c17,20 lyase-inhibitoren
AU2003211574A1 (en) *	2002-03-05	2003-09-16	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
DE10250110A1 (de) *	2002-10-28	2004-05-13	Bayer Cropscience Ag	Thiazol-(bi)cycloalkyl-carboxanilide
JP2006517234A (ja) *	2003-02-10	2006-07-20	アムジエン・インコーポレーテツド	バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
WO2004080972A1 (en)	2003-03-12	2004-09-23	Vertex Pharmaceuticals Incorporated	Pirazole modulators of atp-binding cassette transporters
US7109243B2 (en) *	2003-03-24	2006-09-19	Irm Llc	Inhibitors of cathepsin S
EP1646615B1 (de)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
JP2007507529A (ja) *	2003-09-30	2007-03-29	サイオス・インコーポレーテツド	複素環式アミドおよびスルホンアミド
MXPA06004005A (es)	2003-10-08	2006-06-28	Vertex Pharma	Moduladores de transportadores con casete de union con atp.
JP4869072B2 (ja)	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
MXPA06008606A (es)	2004-01-30	2007-04-13	Vertex Pharma	Moduladores de transportadores con casete de union a atp.
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
EP2363128B1 (de)	2005-03-11	2016-02-17	Vertex Pharmaceuticals Incorporated	Indol-Modulatoren von ATP-bindenden Kassetten-Transportern
EP1891018B1 (de)	2005-05-24	2011-11-16	Vertex Pharmaceuticals, Inc.	Modulatoren von atp-bindenden kassettentransportern
ATE512145T1 (de)	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
AU2006302371A1 (en)	2005-10-06	2007-04-19	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
EP1945632B1 (de)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterozyklische modulatoren von atp-bindenden kassettentransportern
CA2634113A1 (en)	2005-12-24	2007-07-05	Vertex Pharmaceuticals Incorporated	Quinolin- 4 - one derivatives as modulators of abc transporters
AU2006331565A1 (en)	2005-12-27	2007-07-05	Vertex Pharmaceuticals Incorporated	Compounds useful in CFTR assays and methods therewith
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
AU2006336504C9 (en)	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
EP2021797B1 (de)	2006-05-12	2011-11-23	Vertex Pharmaceuticals, Inc.	Zusammensetzungen aus n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxochinolin-3-carboxamid
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
WO2008147952A1 (en)	2007-05-25	2008-12-04	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
HUE028426T2 (en)	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
AU2008298545B2 (en)	2007-09-14	2013-12-12	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2009038683A2 (en)	2007-09-14	2009-03-26	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
WO2009076141A2 (en)	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2639224B1 (de)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Verfahren zur Herstellung von Cycloalkylcarboxamidopyridinbenzoesäuren
JP5637859B2 (ja)	2007-12-13	2014-12-10	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (de)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridylderivate als cftr-modulatoren
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US20100256184A1 (en)	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
JP2012504143A (ja)	2008-09-29	2012-02-16	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
PT2358680E (pt)	2008-10-23	2013-05-14	Vertex Pharma	Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
US8314239B2 (en)	2008-10-23	2012-11-20	Vertex Pharmaceutical Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
NZ592685A (en)	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
EP2382197B1 (de)	2008-12-30	2016-10-05	Vertex Pharmaceuticals Incorporated	Modulatoren des cystic fibrosis transmembrane conductance regulators
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
BR112012006031A2 (pt)	2009-09-17	2019-09-24	Vertex Pharma	processo para preparação de compostos azabicíclicos.
US20110098311A1 (en)	2009-10-22	2011-04-28	Vertex Pharmaceuticals Incorported	Compositions for treatment of cystic fibrosis and other chronic diseases

2004
- 2004-11-15 JP JP2006540025A patent/JP4869072B2/ja not_active Expired - Fee Related
- 2004-11-15 EP EP09164393A patent/EP2140865A1/de not_active Withdrawn
- 2004-11-15 US US10/989,218 patent/US7407976B2/en not_active Expired - Lifetime
- 2004-11-15 NZ NZ547220A patent/NZ547220A/en not_active IP Right Cessation
- 2004-11-15 CA CA002545719A patent/CA2545719A1/en not_active Abandoned
- 2004-11-15 ZA ZA200604578A patent/ZA200604578B/en unknown
- 2004-11-15 RU RU2006120549/04A patent/RU2006120549A/ru not_active Application Discontinuation
- 2004-11-15 KR KR1020067011655A patent/KR20060121185A/ko not_active Withdrawn
- 2004-11-15 EP EP04811321A patent/EP1682127B1/de not_active Expired - Lifetime
- 2004-11-15 CN CN200910142522A patent/CN101675928A/zh active Pending
- 2004-11-15 AU AU2004290581A patent/AU2004290581B2/en not_active Ceased
- 2004-11-15 ES ES04811321T patent/ES2328824T3/es not_active Expired - Lifetime
- 2004-11-15 AT AT04811321T patent/ATE437640T1/de not_active IP Right Cessation
- 2004-11-15 DE DE602004022319T patent/DE602004022319D1/de not_active Expired - Lifetime
- 2004-11-15 MX MXPA06005343A patent/MXPA06005343A/es unknown
- 2004-11-15 WO PCT/US2004/038566 patent/WO2005049018A1/en not_active Ceased
- 2004-11-15 CN CNA2004800394953A patent/CN1925854A/zh active Pending
2006
- 2006-06-13 NO NO20062773A patent/NO20062773L/no not_active Application Discontinuation
2008
- 2008-07-31 US US12/183,580 patent/US7846951B2/en not_active Expired - Lifetime
2010
- 2010-10-27 US US12/913,089 patent/US8232302B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
RU2006120549A (ru)	2007-12-27
CN101675928A (zh)	2010-03-24
JP4869072B2 (ja)	2012-02-01
KR20060121185A (ko)	2006-11-28
US20110144123A1 (en)	2011-06-16
AU2004290581B2 (en)	2011-07-14
MXPA06005343A (es)	2006-07-10
JP2007511538A (ja)	2007-05-10
ZA200604578B (en)	2008-05-28
WO2005049018A1 (en)	2005-06-02
US8232302B2 (en)	2012-07-31
US7407976B2 (en)	2008-08-05
ES2328824T3 (es)	2009-11-18
HK1092353A1 (en)	2007-02-09
EP1682127A1 (de)	2006-07-26
DE602004022319D1 (de)	2009-09-10
AU2004290581A1 (en)	2005-06-02
US7846951B2 (en)	2010-12-07
EP2140865A1 (de)	2010-01-06
EP1682127B1 (de)	2009-07-29
CA2545719A1 (en)	2005-06-02
NZ547220A (en)	2009-12-24
US20050130970A1 (en)	2005-06-16
NO20062773L (no)	2006-08-08
US20090018140A1 (en)	2009-01-15
CN1925854A (zh)	2007-03-07

Legal Events

Date

Code

Title

Description

2010-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1682127

Country of ref document: EP

2011-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE437640T1 (de)	2009-08-15	Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern
DE602004022819D1 (de)	2009-10-08	Von atp-bindende kassette transportern
ATE533749T1 (de)	2011-12-15	Modulatoren von atp-bindenden kassettentransportern
EP2530075A3 (de)	2014-12-24	Modulatoren von Transportern der ATP-bindenden Kassette
EP2363128A3 (de)	2011-09-21	Indol-Modulatoren von ATP-bindenden Kassetten-Transportern
DE60219917D1 (de)	2007-06-14	Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
JP2005528401A5 (de)	2009-06-18
CY1111237T1 (el)	2015-06-11	Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
ATE302753T1 (de)	2005-09-15	Sulfamide als gamma-secretase-inhibitoren
CY1109151T1 (el)	2014-07-02	Αντισωματα dr4 και χρησεις αυτων
BR0002414A (pt)	2001-01-02	Composição cosméticas de proteção à luz fotoestáticas
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
ATE509953T1 (de)	2011-06-15	Antikörper gegen den erythropoietinrezeptor und verwendungen davon
BR0211926A (pt)	2006-12-12	agentes para realçar a resposta imune
ATE405840T1 (de)	2008-09-15	Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
DE602004027490D1 (de)	2010-07-15	Indazol-, benzisoxazol- und benzisothiazol-kinaseinhibitoren
CY1110505T1 (el)	2015-04-29	Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
ATE407698T1 (de)	2008-09-15	Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE430738T1 (de)	2009-05-15	3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DK0796618T3 (da)	2002-05-06	Behandling og profylakse af pankreatitis
WO2005012330A3 (en)	2005-09-09	AMYLOID β-PEPTIDE AND METHODS OF USE
SE0301987D0 (sv)	2003-07-04	New polypeptide
CY1111678T1 (el)	2015-10-07	Σταθεροποιημενες και διατηρημενες οφθαλμικες ενωσεις κετοτιφενης
KR960702835A (ko)	1996-05-23	헤테로사이클릭 화학(Heterocyclic chemistry)
NO20001751L (no)	2000-05-03	Nye forbindelser til bruk som neuroprotektive midler